There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM – Research Report) and Integra Lifesciences (IART – Research Report) with bullish sentiments.
Mirum Pharmaceuticals (MIRM)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Mirum Pharmaceuticals today and set a price target of $69.00. The company’s shares closed last Wednesday at $28.89.
According to TipRanks.com, Wolleben is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $45.50 average price target, a 53.7% upside from current levels. In a report issued on February 27, H.C. Wainwright also maintained a Buy rating on the stock with a $58.00 price target.
See the top stocks recommended by analysts >>
Integra Lifesciences (IART)
In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Integra Lifesciences, with a price target of $49.00. The company’s shares closed last Wednesday at $38.67.
According to TipRanks.com, Turkaly is a 1-star analyst with an average return of
Currently, the analyst consensus on Integra Lifesciences is a Hold with an average price target of $45.33, implying a 10.1% upside from current levels. In a report issued on February 21, Wells Fargo also maintained a Buy rating on the stock with a $49.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MIRM:
